ライフサイエンスコーパス: major depressive disorder

1 No significant difference was found in major depressive disorder.

2 ial evaluated oral NSI-189 as monotherapy in major depressive disorder.

3 s strongly with recurrent and single-episode major depressive disorder.

4 ation in a clinical setting in patients with major depressive disorder.

5 omorbid with other mental disorders, such as major depressive disorder.

6 evant to affect-related illnesses, including major depressive disorder.

7 level are also implicated in the etiology of major depressive disorder.

8 te biomarker of inflammation associated with major depressive disorder.

9 ecoxib administration in treatment-resistant major depressive disorder.

10 positive in bipolar disorder but negative in major depressive disorder.

11 utics, in particular for treatment-resistant major depressive disorder.

12 which has a closer genetic association with major depressive disorder.

13 8 as a biomarker of stress vulnerability and major depressive disorder.

14 ociated with psychiatric disorders including major depressive disorder.

15 dal antidepressant approved for treatment of major depressive disorder.

16 nical trial of sertraline versus placebo for major depressive disorder.

17 that is in development for the treatment of major depressive disorder.

18 including posttraumatic stress disorder and major depressive disorder.

19 ration to BDNF expression is associated with major depressive disorder.

20 ng inflammation pathways in the treatment of major depressive disorder.

21 nesis of stress-related disorders, including major depressive disorder.

22 eby target the underlying pathophysiology of major depressive disorder.

23 studies in women not formally diagnosed with major depressive disorder.

24 in treatment-seeking adult outpatients with major depressive disorder.

25 d it is an effective add-on intervention for major depressive disorder.

26 use of these interventions for prevention of major depressive disorder.

27 ich prior studies indicate is hyperactive in major depressive disorder.

28 ents are a particularly disabling feature of major depressive disorder.

29 II disorder is more strongly correlated with major depressive disorder.

30 ong detrimental effect of BMI on the risk of major depressive disorder.

31 depressants are similar in BD as in unipolar major depressive disorder.

32 gn chronopharmacological strategies to treat major depressive disorder.

33 termediate in bipolar disorder, and least in major depressive disorder.

34 a continuum between depressive symptoms and major depressive disorder.

35 decreased glutamate levels in patients with major depressive disorder.

36 frontal cortex (mPFC) has been implicated in major depressive disorder.

37 arly scores for behavioral disinhibition and major depressive disorder.

38 defeat stress, modeling multiple aspects of major depressive disorder.

39 favorable response for a drug treatment for major depressive disorder.

40 ollectively representing 2,928 patients with major depressive disorder.

41 psychotherapy practice, CBT, in adults with major depressive disorder.

42 ciation between the Netrin-1/DCC pathway and major depressive disorder.

43 POT-FSS to real RNA-Seq data from a study of major depressive disorder.

44 entified genetic variants of SIRT1 linked to major depressive disorders.

45 Andalusian BD multiplex families (166 BD, 78 major depressive disorder, 151 unaffected) as well as 43

46 at the visit were anxiety disorders (20.0%), major depressive disorder (16.9%), and substance use dis

47 cide attempters and 8,786 nonattempters with major depressive disorder; 3,264 attempters and 5,500 no

48 res for schizophrenia, alcohol use disorder, major depressive disorder, a combined bipolar disorder-s

49 magentic resonance imaging in patients with major depressive disorder, a disease associated with an

50 In patients with major depressive disorder, a dysfunctional reward-system

51 ynapses is a primary objective when treating major depressive disorder-a disease that afflicts ~20% o

52 ess disorder and comorbid conditions such as major depressive disorder and alcohol use disorder.

53 linked to pathological circuitry, including major depressive disorder and Alzheimer disease.

54 ly, after puberty, females are more prone to major depressive disorder and anxiety disorders compared

55 disorder, along with the increased rates of major depressive disorder and anxiety disorders in one o

56 larify the shared molecular genetic basis of major depressive disorder and bipolar disorder and to hi

57 genetic associations, and genetic studies of major depressive disorder and bipolar disorder can be co

58 Analyzing subtypes of major depressive disorder and bipolar disorder provides

59 Mood disorders (including major depressive disorder and bipolar disorder) affect 1

60 and genetic association with schizophrenia, major depressive disorder and bipolar disorder.

61 Data were compared with those of women with major depressive disorder and chronic widespread pain (M

62 ly STIR to real RNA-Seq data from a study of major depressive disorder and discuss STIR's straightfor

63 erences of brain anatomy between people with major depressive disorder and healthy control subjects,

64 in a sample comprising 596 participants with major depressive disorder and healthy controls.

65 al brain disorders (including, among others, major depressive disorder and obsessive-compulsive disor

66 -related neuropsychiatric disorders, such as major depressive disorder and posttraumatic stress disor

67 tive ability, neuroticism, bipolar disorder, major depressive disorder and schizophrenia (standardise

68 data were collected for 28 patients (20 with major depressive disorder and seven with bipolar II diso

69 In fact, the bidirectional relation between major depressive disorder and sleep has been well-docume

70 ine the durability and safety of SAGE-217 in major depressive disorder and to compare SAGE-217 with a

71 motivational disorders, including addiction, major depressive disorder, and autism (Cousins et al., 2

72 ring emotional face processing, diagnosis of major depressive disorder, and greater self-reported dep

73 ced excitatory neurotransmission occurs with major depressive disorder, and may be normalized by anti

74 ipants with schizophrenia, bipolar disorder, major depressive disorder, and obsessive-compulsive diso

75 autism spectrum disorder, bipolar disorder, major depressive disorder, and schizophrenia.

76 autism spectrum disorder, bipolar disorder, major depressive disorder, and schizophrenia.

77 and subjects with SZ, bipolar disorder, and major depressive disorder, and the messenger RNA was sub

78 variation, FMRP targets were associated with major depressive disorder, and we present novel evidence

79 rleukin-6 (IL-6) and C-reactive protein with major depressive disorder are well established, evidence

80 and operationalize depression severity, and major depressive disorder as defined in the Diagnostic a

81 -based morphometry studies in schizophrenia, major depressive disorder, bipolar disorder, addiction,

82 e attempt, using cohorts of individuals with major depressive disorder, bipolar disorder, and schizop

83 on large genetic studies of six phenotypes: major depressive disorder, bipolar disorder, attention-d

84 tive primary psychiatric disorders including major depressive disorder, bipolar disorder, schizophren

85 Brain structural abnormalities in major depressive disorder, bipolar disorder, schizophren

86 he highest deletion burdens were observed in major depressive disorder brain, at levels greater than

87 s first-line antidepressants for adults with major depressive disorder, but success is limited and pa

88 Microbiota dysbiosis has been linked to major depressive disorder, but the mechanisms whereby th

89 dMe) and bipolar disorder, and an additional major depressive disorder cohort from UK Biobank (total:

90 Comparison with a matched major depressive disorder cohort revealed significant di

91 Patients with major depressive disorder completed two rtfMRI-nf sessio

92 NRG3 class I was increased in bipolar and major depressive disorder, consistent with observations

93 disorders (schizophrenia, bipolar disorder, major depressive disorder, cross disorder, attention-def

94 genetic correlation was found between PD and major depressive disorder, depressive symptoms, and neur

95 d genetic risk for behavioral disinhibition, major depressive disorder, depressive symptoms, autism s

96 ecular profiles of individuals with PTSD and major depressive disorder despite their high comorbidity

97 Almost two-thirds of patients with major depressive disorder do not achieve remission with

98 d with no therapy did not reduce episodes of major depressive disorder during 1 year.

99 Major depressive disorder emerges from the complex inter

100 Patients with current major depressive disorder exhibited increased fecal inte

101 Adults with major depressive disorder frequently do not achieve remi

102 phenotypes analysed in UK Biobank only were major depressive disorder, generalised anxiety disorder,

103 t outpatients who had a primary diagnosis of major depressive disorder, had a score >=18 on the 17-it

104 he efficacy of dopamine agonists in treating major depressive disorder has been hypothesized to stem

105 Imaging studies of major depressive disorder have reported structural and f

106 dicted a higher likelihood of remission from major depressive disorder in children undergoing PCIT-ED

107 further development as a novel treatment for major depressive disorder in humans.

108 dicted a higher likelihood of remission from major depressive disorder in the PCIT-ED group (B = 0.14

109 Adults with newly diagnosed major depressive disorder in the United States.

110 ropeans that CRY1Delta11 was associated with major depressive disorder, insomnia, and anxiety.

111 ere medication-free 18- to 65-year-olds with major depressive disorder, insomnia, and suicidal ideati

112 Major depressive disorder is a common mental health cond

113 Major depressive disorder is a common mood disorder in t

114 Major depressive disorder is a common psychiatric disord

115 Major depressive disorder is a leading cause of disabili

116 Major depressive disorder is a remarkably common and oft

117 Major depressive disorder is a result of the complex int

118 Major depressive disorder is a significant and costly ca

119 One of the core symptoms of major depressive disorder is anhedonia, an inability to

120 Major depressive disorder is associated with aberrant re

121 Major depressive disorder is associated with raised peri

122 Major depressive disorder is heritable and a leading cau

123 , is effective and safe for the treatment of major depressive disorder is unknown.

124 teristics, the biological characteristics of major depressive disorder may be close to those of HCS.

125 Seventy eight adolescents with major depressive disorder (MDD) (age mean [SD] = 14.9 +/

126 We compare participants diagnosed with Major Depressive Disorder (MDD) (n = 64) to healthy cont

127 Recurrent and chronic major depressive disorder (MDD) accounts for a substanti

128 atic balance in 35 unmedicated subjects with major depressive disorder (MDD) and 25 healthy controls

129 Major depressive disorder (MDD) and Alzheimer's disease

130 Major depressive disorder (MDD) and generalized anxiety

131 Major depressive disorder (MDD) and loneliness are pheno

132 The association between major depressive disorder (MDD) and obesity may stem fro

133 ed to contribute to symptoms associated with major depressive disorder (MDD) and post-traumatic stres

134 acids (LC omega-3 PUFA) have been linked to major depressive disorder (MDD) and preterm birth (PTB),

135 The UK Biobank concurrently assessed Major Depressive Disorder (MDD) and self-reported lifeti

136 Early life adversity (ELA) increases major depressive disorder (MDD) and suicide risk and pot

137 izophrenia (SCZ), bipolar disorder (BD), and major depressive disorder (MDD) are heritable psychiatri

138 Medications to treat major depressive disorder (MDD) are not equally effectiv

139 The neuro-anatomical substrates of major depressive disorder (MDD) are still not well under

140 tly expressed in the brain, in subjects with major depressive disorder (MDD) as compared with age- an

141 d to investigate the changes of olfaction of major depressive disorder (MDD) before and after medical

142 troconvulsive therapy (ECT) is effective for major depressive disorder (MDD) but its effects on memor

143 We used polygenic risk scores for major depressive disorder (MDD) calculated from the resu

144 me (GMV) and HCMV has never been examined in major depressive disorder (MDD) despite the presence of

145 udy investigated intrinsic brain networks in major depressive disorder (MDD) during a depressive epis

146 ee phenome-wide association analyses between major depressive disorder (MDD) genetic risk score (GRS)

147 Major depressive disorder (MDD) has an enormous impact o

148 The neurophysiology of major depressive disorder (MDD) has become a particular

149 the frontotemporal cortices of patients with major depressive disorder (MDD) has been demonstrated us

150 f altered grey and white matter structure in Major Depressive Disorder (MDD) have been inconsistent.

151 Subcortical volumetric changes in major depressive disorder (MDD) have been purported to u

152 Major depressive disorder (MDD) in children and adolesce

153 tritional interventions on the prevention of major depressive disorder (MDD) in overweight adults are

154 Major depressive disorder (MDD) in the elderly is a risk

155 Major depressive disorder (MDD) is a complex condition w

156 Major depressive disorder (MDD) is a debilitating mental

157 Major depressive disorder (MDD) is a leading cause of di

158 More severe anhedonia in major depressive disorder (MDD) is a negative predictor

159 Major depressive disorder (MDD) is a prevalent psychiatr

160 Major depressive disorder (MDD) is a serious mental illn

161 Major depressive disorder (MDD) is a serious, heterogene

162 Major depressive disorder (MDD) is associated with alter

163 Although major depressive disorder (MDD) is associated with alter

164 Major depressive disorder (MDD) is associated with alter

165 Major depressive disorder (MDD) is associated with an in

166 predict treatment response in patients with major depressive disorder (MDD) is challenging, in part

167 Neuroimaging studies have shown that major depressive disorder (MDD) is characterized by abno

168 Distinguishing bipolar disorder (BD) from major depressive disorder (MDD) is clinically challengin

169 owever, evidence for leptin dysregulation in major depressive disorder (MDD) is conflicting.

170 of our knowledge of the biological basis of major depressive disorder (MDD) is derived from studies

171 Although major depressive disorder (MDD) is highly prevalent, its

172 Major depressive disorder (MDD) is moderately heritable,

173 Major depressive disorder (MDD) is the second largest ca

174 Patients with major depressive disorder (MDD) often have structural an

175 of post-traumatic stress disorder (PTSD) and major depressive disorder (MDD) on the basis of robust a

176 e (NMDA channel blocker) in the treatment of major depressive disorder (MDD) over 12 weeks.

177 However, the proportion of never-treated major depressive disorder (MDD) patients who exhibit inf

178 erations of brain functional connectivity in major depressive disorder (MDD) patients with suicidal i

179 fMRI data of 130 individuals (65 melancholic major depressive disorder (MDD) patients, 65 healthy con

180 resistance observed in approximately 30% of major depressive disorder (MDD) patients.

181 inhibitors (SSRIs) are standard of care for major depressive disorder (MDD) pharmacotherapy, but onl

182 Patients with major depressive disorder (MDD) present with heterogeneo

183 ethylome-wide association studies (MWAS) for major depressive disorder (MDD) to identify sites of pot

184 Fewer than 50% of all patients with major depressive disorder (MDD) treated with currently a

185 and genetic data (n = 3907) from the ENIGMA Major Depressive Disorder (MDD) working group.

186 The study participants were 27 subjects with major depressive disorder (MDD), 29 subjects with bipola

187 ty in 50 patients with FEP, 50 patients with major depressive disorder (MDD), 50 patients with post-t

188 idepressant partial- and non-responders with major depressive disorder (MDD), a systematic search of

189 trum condition (ASC), bipolar disorder (BD), major depressive disorder (MDD), and schizophrenia (SCZ;

190 the differences in kynurenine metabolites in major depressive disorder (MDD), bipolar disorder (BD),

191 logy of major psychiatric disorders, such as major depressive disorder (MDD), bipolar disorder (BD),

192 nalyses identified genetic correlations with Major Depressive Disorder (MDD), Bipolar Disorder (BD),

193 om meta-GWASs of self-reported and recurrent major depressive disorder (MDD), bipolar disorder and sc

194 n cortical thickness have been identified in major depressive disorder (MDD), but findings have been

195 Serotonergic dysfunction is implicated in major depressive disorder (MDD), but the mechanisms of t

196 eurotransmission has long been implicated in major depressive disorder (MDD), for which selective ser

197 glia in neuropsychiatric diseases, including major depressive disorder (MDD), has been postulated.

198 5 findings in stress disorders, particularly major depressive disorder (MDD), highlighting insights f

199 ly life adversity (ELA) is a risk factor for major depressive disorder (MDD), however the underlying

200 rcRNAs in psychiatric diseases, particularly major depressive disorder (MDD), remains largely unknown

201 The etiology of major depressive disorder (MDD), the leading cause of wo

202 cy of S-ketamine (esketamine) nasal spray in major depressive disorder (MDD), we performed a genome-w

203 Using RNA-Seq data from a study of major depressive disorder (MDD), we show that NPDR with

204 cortical excitatory to inhibitory balance in major depressive disorder (MDD), which afflicts ~14%-20%

205 or the adjunctive treatment of patients with major depressive disorder (MDD), who did not respond ade

206 rant immune processes in the pathogenesis of major depressive disorder (MDD).

207 al defeat stress (CSDS) and in patients with major depressive disorder (MDD).

208 ysfunction contribute to the pathogenesis of major depressive disorder (MDD).

209 ing its ability to identify individuals with major depressive disorder (MDD).

210 ty and suicidal ideation (SI) in adults with major depressive disorder (MDD).

211 system modulator for adjunctive treatment of major depressive disorder (MDD).

212 sis to study resting-state brain activity in major depressive disorder (MDD).

213 ublic health and is strongly associated with major depressive disorder (MDD).

214 P) and schizophrenia (SCZ), and unchanged in major depressive disorder (MDD).

215 n changes in brain and blood associated with major depressive disorder (MDD).

216 rted in several brain areas of subjects with major depressive disorder (MDD).

217 onin 1A receptor (5-HT1AR) are implicated in major depressive disorder (MDD).

218 ve been implicated in the pathophysiology of major depressive disorder (MDD).

219 in the etiology of mood disorders, including major depressive disorder (MDD).

220 s-associated psychiatric diseases, including major depressive disorder (MDD).

221 on with subcortical anatomy in patients with major depressive disorder (MDD).

222 ients with comorbid mood disorders including major depressive disorder (MDD).

223 -associated disorders later in life, such as major depressive disorder (MDD).

224 most well-documented neural abnormalities in major depressive disorder (MDD).

225 eplicated finding in neuroimaging studies of major depressive disorder (MDD).

226 lammatory pathways and the gut microbiome in major depressive disorder (MDD).

227 (PUFAs) may be efficacious for treatment of major depressive disorder (MDD).

228 have yet to be reported in individuals with major depressive disorder (MDD).

229 cibly increased in a subset of patients with major depressive disorder (MDD).

230 nhibitor treatment outcomes in patients with major depressive disorder (MDD).

231 synaptic plasticity is often associated with major depressive disorder (MDD).

232 IFN-alpha) treatment for Hepatitis-C develop major depressive disorder (MDD).

233 t response has been a clinical challenge for major depressive disorder (MDD).

234 ting antidepressant effects in patients with major depressive disorder (MDD).

235 hizophrenia (SZ), bipolar disorder (BD), and major depressive disorder (MDD).

236 ion (rTMS) is a commonly- used treatment for major depressive disorder (MDD).

237 tom alleviation and quality of life (QoL) in major depressive disorder (MDD).

238 by minimal phenotyping and strictly defined major depressive disorder (MDD): the former has a lower

239 receptor antagonist, ketamine, for treating major depressive disorder (MDD); however, its neural mec

240 have been observed frequently in adults with major depressive disorder (MDD); however, results have b

241 Endothelial dysfunction is evident in major depressive disorder (MDD); however, the molecular

242 rosis (MS, 4,888 cases and 10,395 controls), major depressive disorder (MDD, 1,475 cases and 2,144 co

243 (r g = 0.82, standard error (s.e.) = 0.03), major depressive disorder (MDD; r g = 0.69, s.e. = 0.07)

244 ression models, PSs indexing 6 risk factors (major depressive disorder [MDD], attention deficit/hyper

245 We analyzed data from outpatients with major depressive disorder (n = 124) randomized to receiv

246 Individuals with major depressive disorder (n = 26) and healthy controls

247 211), autism spectrum disorder (N = 126), or major depressive disorder (N = 398; total N = 2937 from

248 We recruited unmedicated patients with major depressive disorder (N = 71 approached; N = 39 ran

249 s possible novel treatment for diseases like major depressive disorder, obesity, chronic pain, and ce

250 y contribute to the heritability of anxiety, major depressive disorder, obsessive-compulsive disorder

251 gnificant enrichments of the heritability of major depressive disorder, obsessive-compulsive disorder

252 urrently in clinical trials for treatment of major depressive disorder, offers the opportunity for th

253 thy controls and from patients with remitted major depressive disorder on antidepressants.

254 ound: one associated with suicide attempt in major depressive disorder, one associated with suicide a

255 luded 67,807 individuals with a diagnosis of major depressive disorder or depressive disorder not oth

256 known about the role(s) of these neurons in major depressive disorder or in mediating the delayed be

257 e intrinsically linked to the development of major depressive disorder, originate in part from the dy

258 CFP connectivity at 1-week post treatment in major depressive disorder patients randomized to 8 weeks

259 were also observed in human fibroblasts from major depressive disorder patients.

260 aptic markers in human NAc from nonmedicated major depressive disorder patients.

261 Applying the major depressive disorder polygenic risk score (MDD-PRS)

262 s depression, and many prominent theories of major depressive disorder propose a role for abnormal co

263 ificantly associated with suicide attempt in major depressive disorder (R(2)=0.25%), bipolar disorder

264 antly negatively genetically correlated with major depressive disorder (r(g)=-0.24) and ADHD (r(g)=-0

265 y correlated with schizophrenia (r(g)=0.22), major depressive disorder (r(g)=0.26), and attention def

266 Most guidelines for major depressive disorder recommend initial treatment wi

267 Effective pharmacotherapy for major depressive disorder remains a major challenge, as

268 environment interaction hypotheses regarding major depressive disorder remains strong despite controv

269 Not all patients with major depressive disorder respond to adequate pharmacolo

270 a (SCZ), bipolar disorder (BD) and recurrent major depressive disorder (rMDD) are common psychiatric

271 A total of 154 medication-free patients with major depressive disorder seeking treatment at two unive

272 otential treatment for severe and refractory major depressive disorder since 2005.

273 non-psychiatric controls (CON, N=29), DSM-IV major depressive disorder suicides (MDD-S, N=21) and MDD

274 antly associated with a greater reduction in major depressive disorder symptoms (r = -.12, p > .4).

275 P was associated with a greater reduction in major depressive disorder symptoms (r = -.24, p = .05).

276 ritability is an important symptom domain of major depressive disorder that is not fully reflected in

277 We searched for all case-control studies on major depressive disorder that reported microarray or RN

278 hods using real RNA-seq data from a study of major depressive disorder.The cnCV method has similar tr

279 armacologic Treatment of Adult Patients with Major Depressive Disorder." The evidence review done for

280 ective samples of SSRI-treated patients with major depressive disorder: the MARS (n = 253, P = 0.0169

281 r predicting the response of 894 adults with major depressive disorder to cognitive behavior therapy.

282 adult outpatients with epilepsy and current major depressive disorder to sertraline or weekly CBT fo

283 Major depressive disorder topped ischemic heart disease

284 e in 33 individuals with treatment-resistant major depressive disorder (TRD) and 25 healthy volunteer

285 by the FDA for treating treatment-resistant major depressive disorder (TRD) in 2019, almost 50 years

286 A total of 116 participants with major depressive disorder treated with sertraline in sta

287 otal of 41 subjects with treatment-resistant major depressive disorder underwent one [(18)F]FEPPA pos

288 Using independent microarray studies of major depressive disorder, we find that including prior

289 In treating major depressive disorder, we lack tests anchored in neu

290 l Manual of Mental Disorders IV criteria for major depressive disorder were eligible and consented to

291 Genes abnormally expressed in major depressive disorder were enriched for innate immun

292 s between schizophrenia/bipolar disorder and major depressive disorder were found in the limbic syste

293 METHOD: Adult outpatients with major depressive disorder were randomly assigned to open

294 low expression are associated with risk for major depressive disorder while those of higher expressi

295 In participants with major depressive disorder who are trained to upregulate

296 he stage 2 sample comprised 87 patients with major depressive disorder who switched medication and 38

297 Major depressive disorder with psychotic features (psych

298 ies from the Psychiatric Genomics Consortium Major Depressive Disorder Working Group and the UK Bioba

299 MS) is an effective treatment for refractory major depressive disorder, yet no studies have character

300 Lithium has been used to treat major depressive disorder, yet the neural circuit mechan